
Last updated: 2026-09-05 11:20:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Tempest Therapeutics, Inc. (TPST) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.03, with a market capitalization of $18.19M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.84 to $6.12. This page covers its latest market performance, valuation, price trends and company information.
$18.19M | |
$1.04 | |
$266.50 | |
$0.84 | |
$1.05 | |
205.47K | |
-- | |
-- | |
$6.12 | |
$0.84 | |
-- | |
-- |
Tempest Therapeutics, Inc. (TPST) last closed at $1.05 as of 2026-09-04 23:31:00, unchanged from the previous close of $1.05.
During the latest regular trading session, TPST traded between $0.84 and $266.50, with a volume of 205.47K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Tempest Therapeutics, Inc. (TPST) moved from $1.06 to $1.03, representing a decline of 3.30% ($0.04).
The stock traded between $1.01 and $1.11 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 128.20 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 3.5%
TPST is currently trading at $1.03, placing it 3.5% of the way from its 52-week low of $0.84 to its 52-week high of $6.12. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 4 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Tempest Therapeutics, Inc. (TPST) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.